Modified Human Immunodeficiency Virus-Based Lentiviral Vectors Display Decreased Sensitivity toTrans-Dominant Rev
- 10 April 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 11 (6) , 895-908
- https://doi.org/10.1089/10430340050015509
Abstract
As a first step toward the development of HIV-based conditionally replicating defective interfering particles expressing trans-dominant Rev (TdRev), we studied whether mutation of the splicing signals and replacement of the RRE by the SRV-1 CTE would render these vectors less sensitive to TdRev. Vectors with mutations in the splicing signals (SD-/RRE+) yielded high titers (5 X 106 CFU/ml) and showed higher levels of cytoplasmic unspliced mRNA than the corresponding SD+/RRE+ vectors either in the absence of Rev, in the presence of TdRev, or in the presence of both TdRev and Rev. Proviral copies of SD-/RRE+ vectors were rescued more efficiently than SD+/RRE+ vectors when TdRev was expressed. Vectors with the SRV-1 CTE (SD+/CTE+ and SD-/CTE+) expressed high levels of cytoplasmic unspliced mRNA in the absence of Rev expression. Titers obtained with the SD-/CTE+ vectors (106 CFU/ml) were higher than the titers obtained with SD+/CTE+ vectors. We also tested the effect of other structural modifications such as the orientation of the expression cassette and the presence of the central polypurine tract (cPPT/CTS). We show that an expression cassette cloned in the reverse orientation with respect to the LTRs or elimination of the cPPT/CTS element severely affected vector titers. We also demonstrated that these vectors can be efficiently mobilized from their proviral state by HIV trans-complementing functions, and transduced into secondary target cells without suffering any genomic rearrangement.Keywords
This publication has 73 references indexed in Scilit:
- Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extensionPublished by Elsevier ,2003
- Inhibition of Human Immunodeficiency Virus Type 1 by Tat/Rev-Regulated Expression of Cytosine Deaminase, Interferon alpha2, or Diphtheria Toxin Compared with Inhibition by Transdominant RevHuman Gene Therapy, 1999
- Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studiesGene Therapy, 1998
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996
- nteractions of INS (CRS) Elements and the Splicing Machinery Regulate the Production of Rev-responsive mRNAsJournal of Molecular Biology, 1996
- Analysis oftrans-Dominant Mutants of the HIV Type 1 Rev Protein for Their Ability to Inhibit Rev Function, HIV Type 1 Replication, and Their Use as Anti-HIV Gene TherapeuticsAIDS Research and Human Retroviruses, 1995
- Transfer of an Anti-HIV-1 Ribozyme Gene into Primary Human LymphocytesHuman Gene Therapy, 1994
- HIV-1 Reverse Transcription A Termination Step at the Center of the GenomeJournal of Molecular Biology, 1994
- HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virusCell, 1989
- Site-directed mutagenesis by overlap extension using the polymerase chain reactionGene, 1989